Amylyx Pharmaceuticals (AMLX) is experiencing a decline in its stock price following the announcement of a public offering of approximately 17.14 million shares at $3.50 per share, aiming to raise around $60 million in gross proceeds. This offering, which includes an option for the underwriter to purchase an additional 2.57 million shares, represents a significant dilution for existing shareholders. The low